10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial

10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial

Introduction Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are major otitis media pathogens that densely co-colonise the nasopharynx and infect the middle ear of Australian Aboriginal infants from very early in life. Our co-primary hypotheses are that at 18 months of age in...

Full description

Bibliographic Details
Main Authors: Jonathan Carapetis, Paul Torzillo, Heidi Smith-Vaughan, Tom Snelling, Mark Chatfield, Amanda Jane Leach, Ross Andrews, Kim Mulholland, Victor M Oguoma, Nicole Wilson, Peter McIntyre, Anne Balloch, Deborah Lehmann, Michael J Binks, Anne Chang, Vicki Krause, Paul Licciardi, Peter Morris
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/5/e033511.full

Internet

https://bmjopen.bmj.com/content/10/5/e033511.full

Similar Items